Top Markets
#1 AntFun AntFun +58.69%
#2 BankrCoin BankrCoin +22.98%
#3 EXOD EXOD +21.04%
#4 ZetaChain ZetaChain +16.29%
#5 Fake World Assets Fake World Assets +14.27%
#6 Venom Venom +12.87%
#7 CARV CARV +10.82%
#8 StonkBroker StonkBroker +10.81%
#9 Black Phoenix Black Phoenix +10.04%
#10 Phala Phala +9.50%
Coin of the day
AntFun AntFun
Settings
Language
ENGLISH
Currency
USD
Theme
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B
Rank in Stocks #107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Share Price
$41.14
Last synced: 2026-09-21
Market Cap
$182.76B
Change (1 day)
-7.78%
Change (1 year)
-32.24%
Country
DK
Trade Novo Nordisk A/S (NOVO-B)

Category

Healthcare
P/E ratio for Novo Nordisk A/S (NOVO-B)
P/E ratio as of September 2026 TTM: 10.69
According to Novo Nordisk A/S latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 10.69. At the end of 2024 the company had a P/E ratio of 27.53.
P/E ratio history for Novo Nordisk A/S from 2000 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) 10.69 -24.21%
2025 14.11 -48.75%
2024 27.53 -26.39%
2023 37.40 -2.28%
2022 38.27 8.25%
2021 35.35 49.61%
2020 23.63 0.26%
2019 23.57 23.65%
2018 19.06 -12.01%
2017 21.66 27.49%
2016 16.99 -42.39%
2015 29.49 14.43%
2014 25.77 21.85%
2013 21.15 -11.44%
2012 23.88 9.42%
2011 21.83 -13.90%
2010 25.35 37.23%
2009 18.48 6.65%
2008 17.32 -27.90%
2007 24.03 1.28%
2006 23.72 19.31%
2005 19.88 -0.71%
2004 20.02 18.71%
2003 16.87 -2.64%
2002 17.33 -43.27%
2001 30.54 -2.36%
2000 31.28 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 38.12 256.42%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 30.79 187.90%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 73.73 589.43%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 22.25 108.04%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 114.95 974.91%
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.